C-reactive protein and serotonin syndrome [1]

American Journal of Psychiatry

Volumn 161, Issue 8, 2004, Pages 1499-

  Ledoux, Mark ^a   Braslow, Kenneth ^a   Brown, Thomas M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CLONAZEPAM; CYPROHEPTADINE; FLUOXETINE; TRAMADOL; TRAZODONE;

ADULT; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DEPRESSION; ELECTROENCEPHALOGRAM; HUMAN; LETTER; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DETERMINATION; SEROTONIN METABOLISM; SEROTONIN SYNDROME;

EID: 3342991549     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.161.8.1499     Document Type: Letter

References (5)

1. Sternbach H: Serotonin syndrome: how to avoid, identify, and treat dangerous drug interactions. Curr Psychiatry 2003; 2:12-24
2. Miller GE, Stetler CA, Carney RM, Freedland KE, Banks WA: Clinical depression and inflammatory risk markers for coronary heart disease. Am J Cardiol 2002; 90:1279-1283
3. Saito M, Ishimitsu T, Minami J, Ono H, Ohrui M, Matsuoka H: Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors. Atherosclerosis 2003; 167: 73-79
4. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I: Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002; 106:1439-1441
5. Tanner FC, Boulanger CM, Luscher TF: Endothelium-derived nitric oxide, endothelin, and platelet vessel wall interaction: alterations in hypercholesterolemia and atherosclerosis. Semin Thromb Hemost 1993; 19:167-175